Upper Respiratory Symptoms
Cough, congestion, sore throat, rhinorrhea
All Pathways
Family MedicineManagement
Upper Respiratory Infection Management (IDSA/CDC)
Upper Respiratory Infection Management (IDSA/CDC): Upper Respiratory Symptoms → Primary Symptom Pattern → Pharyngitis/Sore Throat → Strep Test Result → ...
Pathway Overview
13 steps
Algorithm Steps
13 total
01Start 02Decision Primary Symptom Pattern
Determine syndrome
03Action Pharyngitis/Sore Throat
Assess for Group A Strep
- Use Centor/McIsaac criteria
- Fever, tonsillar exudates, tender anterior cervical nodes, no cough
- Score 0-1: No testing, symptomatic care
- Score 2-3: Rapid strep test
- Score 4+: Empiric treatment or test
04Decision Strep Test Result
Rapid strep or culture
05Action GAS Pharyngitis
Antibiotic treatment
- Penicillin V 500mg BID x 10 days
- Amoxicillin 500mg BID x 10 days
- PCN allergy: Azithromycin 500mg day 1, 250mg days 2-5
- Symptomatic improvement expected 24-48h
06Action Symptomatic Treatment
All URI syndromes
- Hydration and rest
- Acetaminophen or ibuprofen for pain/fever
- Topical/oral decongestants (<3 days)
- Honey for cough (age >1 year)
- Nasal saline irrigation
07Action Return Precautions
When to seek care
- Symptoms worsening after day 3
- Not improved by day 10
- High fever >102°F
- Difficulty breathing
- Severe headache, facial swelling
08Action Viral Pharyngitis
Symptomatic care only
- No antibiotics indicated
- Salt water gargles
- Lozenges, NSAIDs for pain
- Most improve in 7 days
- Path rejoins step 06Shared downstream outcome
09Action Rhinosinusitis
Viral vs bacterial distinction
- <10 days: Likely viral
- ≥10 days without improvement: Consider bacterial
- Severe symptoms (high fever, facial pain) >3 days: Consider bacterial
- Double-worsening: Improving then worse
10Decision Bacterial Sinusitis Criteria Met?
Symptoms ≥10 days OR severe
11Action Bacterial Sinusitis Treatment
Antibiotic options
- First-line: Amoxicillin-clavulanate 875/125mg BID x 5-7 days
- Alt: Doxycycline 100mg BID x 5-7 days
- PCN allergy: Doxycycline or respiratory fluoroquinolone
- Decongestants and saline rinses adjunctive
12Action Watchful Waiting Option
Delayed prescribing strategy
- Appropriate for mild bacterial sinusitis
- Give prescription with instructions to fill if not better in 7 days
- Reduces antibiotic use by 50%
- Ensure patient understands worsening signs
- Path rejoins step 06Shared downstream outcome
13Action Acute Bronchitis
Almost always viral
- Cough predominant, may last 2-3 weeks
- No pneumonia signs (focal findings, dyspnea)
- Antibiotics NOT recommended
- Cough suppressants, honey (adults)
- Inhaler if bronchospasm present
- Path rejoins step 06Shared downstream outcome
Guideline Source
IDSA/CDC Principles of Judicious Antibiotic Prescribing
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address influenza-specific treatment
- COVID-19 considerations not specifically addressed
- Bacterial sinusitis antibiotic choice may vary by resistance patterns
- Does not address immunocompromised patients
- Watchful waiting requires patient education and safety-net
Applicable Regions
USAUUKEU
AU: eTG recommends similar conservative approach
UK: NICE supports delayed prescribing strategy
US: CDC antibiotic stewardship guidelines
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Upper Respiratory Infection Management (IDSA/CDC)?
The Upper Respiratory Infection Management (IDSA/CDC) is a management clinical algorithm for Family Medicine. It provides a structured decision tree to guide clinical decision-making, based on IDSA/CDC Principles of Judicious Antibiotic Prescribing.
What guideline is the Upper Respiratory Infection Management (IDSA/CDC) based on?
This algorithm is based on IDSA/CDC Principles of Judicious Antibiotic Prescribing (DOI: 10.7326/M16-1686).
What are the limitations of the Upper Respiratory Infection Management (IDSA/CDC)?
Known limitations include: Does not address influenza-specific treatment; COVID-19 considerations not specifically addressed; Bacterial sinusitis antibiotic choice may vary by resistance patterns; Does not address immunocompromised patients; Watchful waiting requires patient education and safety-net. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Upper Respiratory Infection Management (IDSA/CDC) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free